SRPX2 and metastatic malignant neoplasm in the lymph nodes: The positive rate of SRPX2 in immunostaining of 161 FFPE specimens was 28% (45/161), and SRPX2 was more highly expressed in patients with lymph node metastasis or high MVD or LVD, and those with high SRPX2 expression had a significantly poorer prognosis than those without.